Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	52.65	56.81	70.17
Short-Term Investments	437.89	248.48	77.31
Cash & Short-Term Investments	490.54	305.28	147.48
Cash Growth	60.69%	107.00%	-
Other Current Assets	8.02	4.52	3.39
Total Current Assets	498.56	309.8	150.87
Net Property, Plant & Equipment	12.89	4.97	4
Other Long-Term Assets	0.99	0.16	0.55
Total Assets	512.43	314.93	155.42
Accounts Payable	4.19	1.95	2.5
Accrued Expenses	12.1	6.08	5.63
Current Portion of Leases	2.76	0.74	0.67
Total Current Liabilities	19.05	8.77	8.8
Long-Term Leases	8.73	0.74	1.48
Other Long-Term Liabilities	-	-	4.2
Total Long-Term Liabilities	8.73	0.74	5.68
Total Liabilities	27.78	9.51	14.48
Common Stock	0.05	0.04	0
Additional Paid-in Capital	719.29	429.66	19.8
Accumulated Other Comprehensive Income	0.55	-0.52	0
Retained Earnings	-235.23	-123.75	-45.44
Total Common Shareholders' Equity	484.65	305.43	-25.63
Minority Interest	-	-	166.58
Shareholders' Equity	484.65	305.43	140.94
Total Liabilities & Equity	512.43	314.93	155.42
Total Debt	11.48	1.48	2.15
Net Cash (Debt)	479.06	303.8	145.33
Net Cash Growth	57.69%	109.04%	-
Net Cash Per Share	12.30	14.65	96.52
Book Value	484.65	305.43	-25.63
Book Value Per Share	12.45	14.73	-17.02
Tangible Book Value	484.65	305.43	-25.63
Tangible Book Value Per Share	12.45	14.73	-17.02

Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q